This is a mobile optimized page that loads fast, if you want to load the real page, click this text.

ARX - Aroa Biosurgery

Jump to new

System

Joined
27 June 2010
Posts
4,225
Reactions
337
Aroa Biosurgery is a soft tissue regeneration company that commenced operations in 2008. Aroa focuses on improving the rate and quality of healing in complex wounds and soft tissue reconstruction.

From over 10 years of research and development, Aroa has developed Endoform®, a proprietary soft tissue regeneration technology platform. Endoform® can temporarily replace damaged tissue by acting as a scaffold in the wound or the soft tissue to grow new tissue. It is used where tissue has been lost or damaged by disease or injury. Currently, Aroa has five commercial products based on the Endoform® technology, alongside a new product development pipeline.

Aroa is based in Auckland, New Zealand, with an additional sales office and distribution function in the United States.

It is anticipated that ARX will list on the ASX on 30 July 2020.

https://aroabio.com
 
still on track for end July

..Aroa is raising $45m as part of the IPO & will list with an indicative market capitalisation of A$225m under the code ARX. Bell Potter and Wilsons are Joint Lead Managers to the IPO.
..
Aroa’s products are covered by a patent portfolio that includes 10 patents and 25 pending patent applications across six patent families
..NZ$22m in product revenue FY20 (ending 31 March 2020) & EBITDA positive

At listing Aroa Founder and CEO Brian Ward will have an 11% shareholding.
 
came on market Friday 25th. ....up 80%
The $45 million raised from the listing will go towards financing Aroa's US expansion. With the Capital raise five times oversubscribed, no institution received a full allocation for what they applied.

Institutional investors that bought into the IPO include Ellerston Capital, Washington H. Soul Pattinson, Firetrail Investments, Perennial Value Management, OC Funds and Regal Funds Management.

Mr Ward retains the largest shareholding following the listing with 11 per cent of the business, while New Zealand venture capital fund Movac, Movac partners Phil McCaw (who is also a board member) and Richard Abbott, and the Aspire NZ Seed Fund make up the other top five shareholders.
Long-time Aroa chairman Jim McLean said the overriding sentiment when the company listed on Friday was "justifiable satisfaction".
 
Top Tip from Tribeca Investment Partners, Jun Bei Liu: Aroa Biosurgery

Aroa is an exceptional growth story. It is at an early commercialisation stage of its product portfolio and has already delivered impressive revenue growth as its products gain a foothold in the large US market. Aroa is currently generating revenue of $22 million which we expect to compound by at least 50 per cent annually over the next three years.
 
It is a bit sluggish compared to other recent medical tech IPO, 4DX, but might be on to another breakout situation. Some neat similarities. Both opened well above IPO price, both saw plenty of volume as early investors monetised (some?) of their holdings, then both had a period of quiescence while holding those early gains more or less (>10% drop) before renewed lift and (subtly increasing) volume?

ARX daily with Volume; blue line is 4DX.... both since IPO

 
AS the Resident Bottom picker I think it has hit the bottom at49c.

Not getting in yet but taking a deep dive into it research wise.
 
Bit of a HO HUM reaction to:

A R OA B IO S UR GE RY M A RC H 2 02 4 4 C – C OM M E N TA RY

Financial Highlights
• Strong cash receipts from customers of NZ$18.0 million, reflecting a continuation of the prior quarter’s step-up in Myriad™ and OviTex™1 /OviTex PRS sales.
• Positive net cash inflows from operations of NZ$0.3 million, exceeding Q4 breakeven expectations.
• Net cash outflows from investing activities reduced to NZ$0.7 million, reflecting continued planned investment into additional manufacturing plant & equipment capacity with completion expected by Q3 FY25.
• The Company achieved a 71% reduction in quarterly cash burn to ~NZ$1 million, ending the year with a strong closing cash balance of NZ$29.5 million.
• FY24 results to be released on Tuesday, 21 May 2024

The FY24 might give these the kick they need. Pretty sure this is close to the bottom but I have a feeling they will meander till something substantial is forthcoming.
 
In Today.

Not good for my tipping comp though.
 
Well it is May 21.
No surprises.
 
After a bit of sideways movement I thought there may be a bit of a turn of direction.

 
Showing signs of life..and in a hot sector attracting money.
 

Attachments

  • ARX 2024-06-09 .jpg
    110.4 KB · Views: 10
Had a flash of exuberance on 25 Jun with huge volume and then it dried up to almost nothing...a volume contraction?
Almost 5% today on low volume.
 

Attachments

  • ARX 2024-07-03 .jpg
    107.8 KB · Views: 9
.
.mentioned in

The small and mid-cap biotechs poised for a big breakout

...according to HB Biotechnology’s Charlie Williams.
www.livewiremarkets.com
.
Aroa Biosurgery (ASX: ARX) is another stock that has traded down in recent times, in their case due to earnings downgrades in FY24.

However, their inventory issues and downgrades appear to be behind them and are likely on track for a maiden profit this financial year. Additionally, despite its strong revenue growth profile, Aroa remains below industry peers on an EV/Revenue basis
 
26 Nov ..Financial Highlights
• Product Sales grew by 25% (27% on a constant currency basis) to NZ$39.1 million (NZ$37.3 million on a constant currency basis) compared to H1 FY24.
• Sales of Myriad™ grew by 45% (45% on a constant currency basis) to NZ$14.8 million (NZ$14.1 million on a constant currency basis) compared to H1 FY24.
• Myriad continues leading growth, accounting for 38% of H1 FY25 total product sales and reflecting 72% of AROA’s direct sales mix.
• TELA Bio’s sales of OviTex™ and OviTex PRS increased by 19% during H1 FY25 compared to H1 FY24.
• Total reported H1 FY25 revenue inclusive of project fees grew 23% to NZ$39.2 million
• H1 FY25 normalised EBITDA loss of NZ$1.5 million compared to a loss of NZ$2.7 million in H1 FY24.
• Product gross margin of 87% (86% on a constant currency basis), an increase of 3% (increase of 3% on a c.c. basis) on H1 FY24.
• The company remains debt-free with a cash balance of NZ$21.6 million as at 30 September 2024, providing adequate cash as the company advances towards positive cashflows.
• Full-year FY25 guidance maintained at NZ$80-87 million total revenue, (21-32% increase on FY24 on a constant currency basis), and a normalised EBITDA profit of NZ$2-6 million.

 
You must log in or register to reply here.

Similar threads

OCC - Orthocell Limited
2 3
Replies
43
Views
12K
access
A
Menu
Log in
Register
Cookies are required to use this site. You must accept them to continue using the site. Learn more...